Faculty

Norbert F.Voelkel, M.D.
Professor of Medicine

EDUCATION/TRAINING

University of Wurzburg – Wurzburg, Germany
1965-1968M.D.Pre-Clinical

University of Hamburg – Hamburg, Germany
1968-1971 Medicine

University Hospital Medical School – Hamburg, Germany
1972-1977Intern/Resident

University of Colorado Denver, Denver, CO
1977-1981FellowPulmonary

 UCD
4200 E. Ninth Ave.
Denver, CO 80262
Tel: 303.315.4475
Norbert.Voelkel@uchsc.edu

PROFESSIONAL EXPERIENCE

1992 - present
Director, Pulmonary Hypertension Center - University of Colorado Denver, Denver, CO

1991
Professor of Medicine, Pulmonary Division - University of Colorado Denver, Denver, CO

1990-1991
Clinical Pharmacology - Vanderbilt University, Nashville, TN (Sabbatical)

1986-1991
Associate Professor of Medicine - University of Colorado Denver, Denver, CO

1981-1986
Assistant Professor of Medicine - University of Colorado Denver, Denver, CO

1977-1981
Pulmonary Fellow (Research), Pulmonary Division - University of Colorado Denver, Denver, CO

1975-1977
Senior Resident, Chief Resident – University of Hamburg

PUBLICATIONS (SELECTED FROM 250)

  1. Chang S, Feddersen CO, Henson PM, Voelkel NF. Platelet activating factor mediates hemodynamic changes and lung injury in endotoxin treated rats. J Clin Invest 79:1498-1509, 1987.
  2. Mecham RP, Whitehouse LA, Wrenn DS, Parks WC, Griffin GL, Senior RM, Crouch EC, Stenmark KR, Voelkel NF. Smooth muscle-mediated connective tissue remodeling in pulmonary hypertension. Science 237:423-426, 1987.
  3. Haroldsen PE, Voelkel NF, Henson JE, Murphy RC. Metabolism of platelet-activating factor in isolated perfused rat lungs. J Clin Invest 79:1860-1867, 1987.
  4. Badesch DB, Zapp LM, Westcott JY, Hester J, Orton EC, Voelkel NF, Stenmark KR. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Resp Cell Mol Biol 1:489-498, 1989.
  5. Sala A, Voelkel NF, Maclouf J, Murphy RC. LTE4 elimination and metabolism in normal human subjects. J Biol Chem 265:21771-21778, 1990.
  6. Ono S, Westcott JY, Voelkel NF. PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. J Appl. Physiol. 73(3): 1084-1092, 1992.
  7. NF Voelkel, J Czartolomna, J Simpson, RC Murphy. FMLP causes eicosanoid-dependent vasoconstriction and edema in endotoxin primed lungs. Am Rev Respir Dis 145, 1992.
  8. Panos, RJ, NF Voelkel, GR Cott, RJ Mason, JY Westcott. Alterations in eicasanoid production by rat alveolar Type II cells isolated after silica-induced lung injury. J Resp Cell Mol Biol., 6:430-438, 1992.
  9. Ono, S., JY Westcott, S Chang, and NF Voelkel. Endotoxin priming followed by high altitude causes pulmonary edema in rats. J Appl Physiol 74, 1993.
  10. J Haynes, JR Aubrey, E Taylor, D Dixon, and N Voelkel. Microvascular hemodynamics in the sickle red blood cell perfused isolated rat lung. Am J Physiol 264 (Heart Circ Physiol 33): H484-489, 1993.
  11. RM Tuder, B. Groves, D.B. Badesch, and NF Voelkel. Exuberant Endothelial cell growth and elements of Inflammation are present in plexiform lesions of pulmonary hypertension. Amer J Pathol 144(2):275-285, 1994.
  12. Voelkel NF, RM Tuder, J Bridges and WP Arend. Interleukin-1 Receptor Antagonist Treatment Reduces Pulmonary Hypertension Generated in Rats by Monocrotaline. Am J Respir Cell Mol Biol 11:664-675, 1994.
  13. Tuder RM, Flook B, Voelkel NF. Increased gene expression for VEGF and VEGF receptors KDR/Flk and Flt in lungs of chronically hypoxic rats. J Clin Invest 95:1798-1807, 1995.
  14. Voelkel NF, Lobel K, Westcott JY, Burke TJ. Nitric oxide-related vasoconstriction in lungs perfused with red cell lysate. FASEB J 9:379-386, 1995.
  15. Wade ML, Voelkel NF, Fitzpatrick FA. Suicide inactivation of prostaglandin I2 synthase: Characterization of mechanism-based inactivation with isolated enzyme and endothelial cells. Arch Biochem Biophys 321:453-458, 1995.
  16. Tissot Van Patot MC, MacKenzie S, Tucker A, Voelkel NF. Endotoxin-induced adhesion of red blood cells to pulmonary artery endothelial cells. J Appl Physiol Lung Cell Mol Physiol 270:L28-L36, 1996.
  17. Chida M, Voelkel NF. Acute but not chronic hypoxia upregulates lung cyclooxygenase-2 gene via prostacyclin. Am J Physiol Lung Cell Mol Physiol 270:L872-L878, 1996.
  18. Voelkel NF, Tuder RM, Lepley RA, Fitzpatrick FA. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest 97:2491-2498, 1996.
  19. L Wright, RM Tuder, J Wang, CD Cool, RA Lepley, NF Voelkel. 5-Liposygenase and 5-liposygenase activity protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Amer J Resp Crit Care. 156, 1997.
  20. BD Lowes, W Minobe, WT Abraham, M Riseq, T Bohlmeyer, R Quaife, RL Roden, DL Dutcher, NF Voelkel, DB Badesch, BE Groves, EM Gilbert, MR Bristow. Changes in gene expression in the intact human heart: down-regulation of a-myosin heavy chain in hypertrophied, failing human ventricular myocardium. J Clin Invest 100:2315-2324, 1997.
  21. S-D Lee, KR Shroyer, NE Markham, CD Cool, NF Voelkel, RM Tuder. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest (Rapid Commun). 101:927-934, 1998.
  22. JP Maloney, CC Silliman, DR Ambruso, J Wang, RM Tuder, NF Voelkel. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol Resp Cell Mole Biol 44:H1054-H1061, 1998.
  23. NF Voelkel, C Cool, SD Lee, L Wright, MW Geraci, Rm Tuder. Primary pulmonary hypertension between inflammation and cancer. Chest 114:225S-230S, 1998.
  24. NF Voelkel, JD Allard, SM Anderson , TJ Burke. cGMP and cAMP cause pulmonary vasoconstriction in the presence of hemolysate. J App Physiol 1999.
  25. R Tuder, MW Geraci, J Wang, CD Cook, SH Abman, L Wright, D Badesch, NF Voelkel. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Amer J Resp Crit Care Med June 1999.
  26. MW Geraci, B Gao, DC Shepherd, MD Moore, JY Westcott, LA Alger, RM Tuder, NF Voelkel. Selective pulmonary prostacyclin synthase overexpression in transgenic mice protects against the development of hypoxic pulmonary hypertension. J Clin Invest, 103:1509-1515, 1999.
  27. R Tuder, MW Geraci, J Wang, CD Cook, SH Abman, L Wright, D Badesch, NF Voelkel. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Amer J Resp Crit Care Med, 159:1925-1932, 1999.
  28. CD Cool, JS Stewart, P Werahera, GJ Miller, RL Williams, NF Voelkel, RM Tuder. Three dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Path, In Print.
  29. Y Kasahara, RM Tuder, CD Cool, DA Lynch, SC Flores, NF Voelkel. Endothelial cell death and decreased expression of vascular endothelial growth factor and its receptor KDR/Flk-1 in smoking-induced emphysema. Lancet. Submitted.
  30. M Jakkula, TD LeCras, S Gebb, KP Hirth, RM Tuder, NF Voelkel, SH Abman. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiology. Submitted
  31. M Taraseviciene, Y Kasahara, L. Alger, P Hirth, G McMahon, J Waltenberger, NF Voelkel, RM Tuder. Inhibition of the VEGF receptor-2 combined with chronic hypoxia causes severe pulmonary hypertension with pulmonary endothelial cell proliferation. FASEB J, In Print.
  32. NF Voelkel, RM Tuder. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest 2000; In print.